日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study

Risankizumab治疗日本中重度掌跖脓疱病患者:来自随机3期JumPPP研究的结果

Okubo, Yukari; Murakami, Masamoto; Kobayashi, Satomi; Tsuji, Shigeyoshi; Kishimoto, Mitsumasa; Ikeda, Kimitoshi; Jibiki, Maiko; Neimark, Ezequiel; Padilla, Byron; Shen, Jie; Peters, Sydney; Terui, Tadashi

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.

Risankizumab治疗溃疡性结肠炎:两项随机临床试验

Louis Edouard, Schreiber Stefan, Panaccione Remo, Bossuyt Peter, Biedermann Luc, Colombel Jean-Frederic, Parkes Gareth, Peyrin-Biroulet Laurent, D'Haens Geert, Hisamatsu Tadakazu, Siegmund Britta, Wu Kaichun, Boland Brigid S, Melmed Gil Y, Armuzzi Alessandro, Levine Phillip, Kalabic Jasmina, Chen Su, Cheng Ling, Shu Lei, Duan W Rachel, Pivorunas Valerie, Sanchez Gonzalez Yuri, D'Cunha Ronilda, Neimark Ezequiel, Wallace Kori, Atreya Raja, Ferrante Marc, Loftus Edward V Jr

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial

在一项随机3期试验中,Risankizumab维持治疗可维持克罗恩病患者的诱导反应。

Ferrante, Marc; Irving, Peter M; Abreu, Maria T; Axler, Jeffrey; Gao, Xiang; Cao, Qian; Fujii, Toshimitsu; Rausch, Astrid; Torres, Joana; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; Kligys, Kristina; Berg, Sofie; Liao, Xiaomei; Zhou, Qing; Kalabic, Jasmina; Feagan, Brian; Panaccione, Remo

Content Validity and Psychometric Evaluation of the Crohn's Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn's Disease

克罗恩病症状严重程度(CSS)问卷在中重度活动性克罗恩病患者中的内容效度和心理测量学评价

Louis, Edouard; Lee, Wan-Ju; Litcher-Kelly, Leighann; Ollis, Sarah; Pranschke, Emma; Fitzgerald, Kristina; Lacerda, Ana Paula; Neimark, Ezequiel; Sanchez Gonzalez, Yuri; Panés, Julian

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease

使用体外注射器给药的利沙珠单抗治疗中重度克罗恩病的疗效、安全性、患者体验和耐受性

Loftus, Edward V Jr; Griffith, Jenny; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; Nannapaneni, Sujani; Zhou, Ji; Byrne, Rachel; Kligys, Kristina; Pang, Yinuo; Liao, Xiaomei; Kalabic, Jasmina; Dubinsky, Marla

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease

匹配调整后的间接比较:Risankizumab 与 Ustekinumab 用于中重度活动性克罗恩病诱导和维持治疗的疗效

Dubinsky, Marla; Ma, Christopher; Griffith, Jenny; Crowell, Marjorie; Neimark, Ezequiel; Kligys, Kristina; O'Connell, Tom

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

使用阿达木单抗治疗严格控制克罗恩病具有成本效益:CALM试验的经济评估

Panaccione, Remo; Colombel, Jean-Frederic; Travis, Simon P L; Bossuyt, Peter; Baert, Filip; Vaňásek, Tomáš; Danalıoğlu, Ahmet; Novacek, Gottfried; Armuzzi, Alessandro; Reinisch, Walter; Johnson, Scott; Buessing, Marric; Neimark, Ezequiel; Petersson, Joel; Lee, Wan-Ju; D'Haens, Geert R